ZA200306541B - Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin. - Google Patents

Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin.

Info

Publication number
ZA200306541B
ZA200306541B ZA200306541A ZA200306541A ZA200306541B ZA 200306541 B ZA200306541 B ZA 200306541B ZA 200306541 A ZA200306541 A ZA 200306541A ZA 200306541 A ZA200306541 A ZA 200306541A ZA 200306541 B ZA200306541 B ZA 200306541B
Authority
ZA
South Africa
Prior art keywords
tegafur
carboplatin
paclitaxel
uracil
administration
Prior art date
Application number
ZA200306541A
Other languages
English (en)
Inventor
Jafferhusen A Ajani
Terry S Dugan
Steven E Benner
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA200306541B publication Critical patent/ZA200306541B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200306541A 2001-03-06 2003-08-21 Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin. ZA200306541B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27357701P 2001-03-06 2001-03-06

Publications (1)

Publication Number Publication Date
ZA200306541B true ZA200306541B (en) 2004-11-22

Family

ID=23044526

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200306541A ZA200306541B (en) 2001-03-06 2003-08-21 Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin.

Country Status (20)

Country Link
US (1) US6770653B2 (https=)
EP (1) EP1368034A1 (https=)
JP (1) JP2005506294A (https=)
KR (1) KR20030081496A (https=)
BR (1) BR0207443A (https=)
CA (1) CA2439676A1 (https=)
CZ (1) CZ20032266A3 (https=)
EE (1) EE200300429A (https=)
HR (1) HRP20030801A2 (https=)
HU (1) HUP0303466A3 (https=)
IL (1) IL157357A0 (https=)
IS (1) IS6925A (https=)
MX (1) MXPA03007989A (https=)
NO (1) NO20033910L (https=)
PL (1) PL363967A1 (https=)
RU (1) RU2284184C2 (https=)
SK (1) SK10602003A3 (https=)
WO (1) WO2002076459A1 (https=)
YU (1) YU69903A (https=)
ZA (1) ZA200306541B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
CN1761665A (zh) 2003-03-14 2006-04-19 大鹏药品工业株式会社 抗肿瘤效果增强剂和抗肿瘤剂
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
EP1827500B1 (en) * 2004-10-26 2009-05-06 Pharma Mar S.A., Sociedad Unipersonal Pegylated liposomal doxorubicin in combination with ecteinescidin 743
ATE368461T1 (de) 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2008202078B2 (en) * 2007-10-10 2012-05-31 Wellkey Holdings Limited Stability of secondary metabolite mass production through synchronized plant cell cultures
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
US20180085377A1 (en) * 2015-04-22 2018-03-29 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
IL265044B2 (en) 2016-08-31 2025-02-01 Fujifilm Corp An antitumor preparation containing the substances nab-paclitaxel and 1-(2-deoxy-2-fluoro-4-thio-D-beta-arabinofurnosyl)cytosine, a kit containing these substances and their uses
RU2646450C1 (ru) * 2017-05-11 2018-03-05 Владимир Михайлович Курусин Способ лечения предраковых и ранних стадий раковых заболеваний желудка
WO2019146130A1 (ja) 2018-01-29 2019-08-01 富士フイルム株式会社 胆道がん用抗腫瘍剤および胆道がんの処置方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4328229A (en) 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5534513A (en) 1991-09-05 1996-07-09 Taiho Pharmaceutical Company, Ltd. Antitumor potentiator and antitumor composition
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
RU2194541C1 (ru) * 2001-07-13 2002-12-20 Научно-исследовательский институт онкологии Томского научного центра СО РАН Способ комбинированного лечения больных местнораспространенным раком желудка

Also Published As

Publication number Publication date
JP2005506294A (ja) 2005-03-03
EP1368034A1 (en) 2003-12-10
HUP0303466A2 (hu) 2004-01-28
SK10602003A3 (en) 2004-10-05
WO2002076459A1 (en) 2002-10-03
CZ20032266A3 (cs) 2004-02-18
YU69903A (sh) 2006-08-17
RU2284184C2 (ru) 2006-09-27
HUP0303466A3 (en) 2005-02-28
HRP20030801A2 (en) 2004-08-31
RU2003129527A (ru) 2005-03-10
IL157357A0 (en) 2004-02-19
IS6925A (is) 2003-08-22
EE200300429A (et) 2003-12-15
PL363967A1 (en) 2004-11-29
NO20033910L (no) 2003-10-23
US6770653B2 (en) 2004-08-03
KR20030081496A (ko) 2003-10-17
CA2439676A1 (en) 2002-10-03
BR0207443A (pt) 2004-04-06
NO20033910D0 (no) 2003-09-04
US20020173482A1 (en) 2002-11-21
MXPA03007989A (es) 2003-12-04

Similar Documents

Publication Publication Date Title
ZA200306541B (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin.
WO1999054326A8 (de) Dihydropyrimidine
WO2003080582A3 (de) Fredericamycin-derivate
IL162348A (en) Oxaliplatin formulations, method for stabilizing same and use thereof for preparing medicaments for treating cancer
MXPA03000873A (es) Derivados de quinazolina, medicamentos que contienen estos compuestos, su uso y metodos para la produccion de los mismos.
WO2002062763A3 (en) Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas
WO2002085857A3 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
HK1047236A1 (zh) 用表皮生长因子受体拮抗剂治疗难治的人肿瘤
MXPA02011458A (es) Derivados de acilfenilurea, metodos para su produccion y uso de los mismos como farmacos.
HUP0402588A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them, process for producing them and their use
MXPA03005019A (es) Derivados de difenilazetidinonas, metodo para su produccion farmacos que contienen estos compuestos y su uso.
WO2004080418A3 (en) Nucleic acid compounds for inhibiting angiogenesis and tumor growth
DK1200412T3 (da) Antiproliferative imidazolforbindelser
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
MXPA03006538A (es) Nuevos derivados de urea, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion.
PL378369A1 (pl) Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji
MXPA03001484A (es) Quinazolinas, medicamentos que contienen estos compuestos, y son efectivos como inhbidores de tirosina quinasa, su utilizacion y metodos para su produccion.
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
AU2001240001A1 (en) Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
MXPA03009681A (es) METODO PARA TRATAMIENTO DE TUMORES POR ADMINISTRACIoN DE TEGAFUR, URACILO, ACIDO FOLINICO, Y CICLOFOSFAMIDA.
ZA200302159B (en) New compounds derived from quinazoline, a process for their preparation and pharmaceutical compositions containing them.
EP1208840A3 (en) Combination of fluorouracil and a methylol transfer agent for the treatment of tumor metastases and cancer
WO2000061551A3 (de) Pyrimidin-2-on derivate als integrinrezeptorliganden
HK1060518A (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.